Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications.
Australia was one of the first countries to introduce government-funded unrestricted access to direct-acting antiviral (DAA) therapy, with 88,790 treated since March 2016. However, treatment uptake is declining which could potentially undermine Australia's progress towards the WHO HCV elimination ta...
Guardat en:
| Autors principals: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Public Library of Science (PLoS)
2021-01-01
|
| Col·lecció: | PLoS ONE |
| Accés en línia: | https://doi.org/10.1371/journal.pone.0257369 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|